Business
Update on Investigation, Interims and Auditors
SkinBioTherapeutics plc has completed its board investigation into financial statements, including those for the year ended 30 June 2025, and anticipates publishing its HY26 results alongside restated FY25 results and remediation plans shortly, after which trading in its ordinary shares is expected to resume. The company has appointed Saffrey LLP as its independent auditor for the financial year ending 30 June 2026, following a competitive tender process, and Gravita Audit II Limited has confirmed no circumstances require attention regarding its cessation of office. Disclaimer*
About this update from Skinbiotherapeutics Plc
SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Company" or the "Group") Update on the Board Investigation and Interim Results Appointment of Auditors 28 May 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that its investigation into, inter alia, the financial statements for the year ended 30 June 2025 is complete. Consequently, the Board expects that the HY26 results, together with the restated (unaudited) FY25 results, will be published shortly, along with the resulting actions both taken and planned in respect of the findings of its investigation. The Board anticipates that trading in the Company's ordinary shares will resume following publication of those results. Whilst the Board had expected to publish the HY26 results by the end of May, there were some difficulties in obtaining all the information and evidence which the investigating committee considered to be relevant, and finalising our remediation plans have therefore been slightly delayed. Following the conclusion of a formal competitive tender process, the Company has appointed Saffrey LLP as the Company's independent auditor for the financial year ending 30 June 2026 with immediate effect. Any proposal to reappoint Saffrey LLP as independent auditor for the financial year ending 30 June 2027 will be subject to approval by the Company's shareholders at the next annual general meeting to be held in 2026. Gravita Audit II Limited, the Company's outgoing independent auditor, has confirmed that there are no circumstances connected with it ceasing to hold office that need to be brought to the attention of members or creditors of the Company for the purposes of section 519 of the Companies Act 2006. -Ends- For more information please contact: SkinBioTherapeutics plc Martin Hunt, Executive Chairman Rachel Parsonage, Interim CEO Emily Bertram, CFO [email protected] Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Patrick Weaver +44 (0) 020 7496 3000 Vigo Consulting Melanie Toyne-Sewell, Rozi Morris +44 (0) 20 7390 0230 [email protected] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®...
View stock analysis, news, and events for Skinbiotherapeutics Plc